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Perspective: A randomized comparison of amiodarone versus
dronedarone is in progress. Even if dronedarone proves less
efficacious for AF prevention, because of freedom from risk
of organ toxicity and shorter half-life, it probably will largely
displace amiodarone for the treatment of AF. An exception
is the subgroup with severe HF in which dronedarone may
increase mortality, whereas amiodarone does not.  
Summary written by: Fred Morady, MD
Continuous Improvements in “Chain of Survival”
Increased Survival After Out-of-Hospital Cardiac
Arrests: A Large-Scale Population-Based Study
Iwami T, Nichol G, Hiraide A, et al.
Circulation 2009;119:728-734.
Study Design: Do improvements in emergency medical serv-
ices (EMS) increase survival after out-of-hospital cardiac
arrest (OHCA)?
Methods: This was a prospective cohort study of 8,872
patients (mean age 70 years) with witnessed OHCA of pre-
sumed cardiac origin treated by EMS in Osaka, Japan from
1998 to 2006. As the study evolved, EMS personnel were
encouraged to more quickly deliver shocks and were allowed
to insert endotracheal tubes, and educational programs in
bystander cardiopulmonary resuscitation (CPR) became
more widespread.
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Arrhythmias
Effect of Dronedarone on Cardiovascular Events in
Atrial Fibrillation
Hohnloser SH, Crijns HJ, van Eickels M, et al., on behalf of the ATHENA
Investigators.
N Engl J Med 2009;360:668-678.
Study Design: Does dronedarone decrease the risk of cardio-
vascular events?
Methods: In this double-blind study, 4,628 patients (mean age
72 years) with atrial fibrillation (AF) and ≥1 risk factor for
death (e.g., age >75 years, hypertension, diabetes) were ran-
domly assigned to receive dronedarone, 400 mg twice/day (n =
2,301) or placebo (n = 2,327). Patients with class IV heart
failure (HF) were excluded. All patients were followed for ≥1
year.
Results: The following outcomes were significantly less
prevalent in the dronedarone group than in the placebo
group: the 1° outcome (32% vs. 39%), first hospitalization
for a cardiovascular event (29% vs. 37%), first hospitaliza-
tion for AF (15% vs. 22%), death from a cardiovascular
cause (2.7% vs. 3.9%), and death from an arrhythmia (1.1%
vs. 2.1%). Dronedarone was discontinued because of an
adverse event more often than placebo (12.7% vs. 8.1%).
Conclusions: Dronedarone reduces the risk of major cardio-
vascular events in patients with AF.
abnormal QTc. An abnormal QTc, diabetes, and use of QT-
prolonging drugs all are independently predictive of SCD.
Perspective: Interestingly,  QT-prolonging drugs were associ-
ated with SCD independent of the QTc. Because QTc
prolongation is the only known mechanism by which QT-
prolonging drugs predispose to SCD, the most likely
explanation is QTc variability and the absence of an electro-
cardiogram recorded shortly before SCD. Also, many
patients had idiopathic QTc prolongation, suggesting a
genetic basis such as single-nucleotide polymorphisms. 
Summary written by: Fred Morady, MD 
Electrophysiological Effects of Late Percutaneous
Coronary Intervention for Infarct-Related 
Coronary Artery Occlusion. The Occluded Artery
Trial-Electrophysiological Mechanisms (OAT-EP)
Rashba EJ, Lamas GA, Couderc JP, et al., on behalf of the OAT-EP
Investigators.
Circulation 2009;119:779-787.
Study Design: Does late reperfusion of an infarct-related
artery (IRA) affect markers of vulnerability to ventricular
arrhythmias?
Methods: Three hundred patients (mean age 57 years) in sinus
rhythm and without a bundle branch block were randomly
assigned to percutaneous coronary intervention (PCI) of the
IRA (n = 149) or medical therapy (n = 151) at 3-28 days after
an acute myocardial infarction (MI). Heart rhythm variability
(HRV), filtered QRS duration on a signal-averaged electro-
cardiogram, and T-wave variability (TWV) were measured at
baseline and 1 year.
Results: There was no significant change in α1 at 1 year either
in the PCI or control group. There also were no significant
differences between the PCI and control groups in changes in
filtered QRS or TWV.
Conclusions: Compared to medical therapy, late PCI of an
IRA does not affect changes in HRV, QRS duration, or
TWV during the first year after MI.
Perspective: HRV, filtered QRS duration, and TWV are
noninvasive measures of autonomic tone, slow conduction,
and repolarization, respectively. These three factors affect
the risk of ventricular tachycardia/fibrillation. The main por-
tion of the Occluded Artery Trial demonstrated that late
reperfusion of an IRA does not reduce the risk of sudden
death or ventricular tachycardia in the first year after MI,
and the results of this study are consistent with this. 
Summary written by: Fred Morady, MD 
Results: During the 8 years of this study, neurologically-intact
1-month survival increased significantly from 2% to 6%, due
to bystander CPR (which increased from 19% of OHCAs to
36%), time from collapse to CPR (which shortened from a
median of 9 to 7 minutes), and time from collapse to first
shock (which shortened from a median of 19 to 9 minutes).
Conclusions: An increase in bystander CPR and improvements
in EMS result in a higher probability of survival after
OHCA.
Perspective: The conclusions are not surprising, but it is reas-
suring that a large, population-based study was able to
confirm the results of smaller studies that demonstrated sim-
ilar findings. Of note is that neurologically-intact 1-month
survival tripled during the course of this study, but remained
quite poor in absolute terms (6%). However, the study was
performed before the introduction of compression-only
CPR, which would be likely to additionally improve survival
of patients with OHCA. 
Summary written by: Fred Morady, MD 
Determinants of Prolonged QT Interval and Their
Contribution to Sudden Death Risk in Coronary
Artery Disease: The Oregon Sudden Unexpected
Death Study
Chugh S, Reinier K, Singh T, et al.
Circulation 2009;119:663-670.
Study Design: Is the corrected QT interval (QTc) predictive of
sudden cardiac death (SCD) in patients with coronary artery
disease (CAD)?
Methods: This was a case-control study of 373 patients (mean
age 70 years) with CAD and SCD who had a pre-SCD elec-
trocardiogram suitable for measurement of the QTc and 309
controls (mean age 64 years) who had CAD without SCD.
The criterion for an abnormal QTc was >450 ms in men and
>470 ms in women.
Results: An abnormal QTc was significantly more common
among cases (39%) than controls (21%), and the mean QTc
was significantly longer among the cases (450 ms) than con-
trols (433 ms). Variables independently associated with QTc
prolongation were female gender, diabetes, and use of QT-
prolonging drugs. Independent predictors of SCD were an
abnormal QTc, diabetes, and use of QT-prolonging drugs.
The odds ratio of SCD was 5.5 in patients with an abnormal
QTc who did not have diabetes and who were not taking a
QT-prolonging drug.
Conclusions: Among patients with CAD, gender, diabetes, and
use of QT-prolonging drugs are significant predictors of an
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mitral valve repair surgeon, and the local rates of operative
morbidity and mortality.  
Summary written by: David S. Bach, MD
General Cardiology
Weekend Versus Weekday Admission and
Mortality After Acute Pulmonary Embolism
Aujesky D, Jimenez D, Mor MK, Geng M, Fine MJ, Ibrahim SA.
Circulation 2009;119:962-968.
Study Question: Is there an association between weekend ver-
sus weekday admission and mortality or length of stay for
patients hospitalized with pulmonary embolism (PE)?
Methods: This analysis of data from the Pennsylvania Health
Care Cost Containment Council (PHC4), a database for 186
nongovernmental hospitals in Pennsylvania, identified all
patients with PE discharged between January 2000 and
November 2002. The authors used a discrete survival model
to study the association of weekend versus weekday admission
and time to discharge, adjusting for hospital and patient char-
acteristics, and use of thrombolytic therapy. Patient’s severity
of illness was quantified using the Pulmonary Embolism
Severity Index (PESI).
Results: Among 15,531 patients with PE, 3,286 (21.2%) were
admitted on a weekend. These patients had a higher unad-
justed 30-day mortality rate (11.1% vs. 8.8%), but no
difference in length of stay. After adjustment, patients admit-
ted on the weekend had a greater chance of dying (odds ratio
[OR], 1.17; 95% confidence interval [CI], 1.03-1.34) versus
those admitted on a weekday. Weekend subjects had higher
pulse rate, respiratory rate, rate of altered mental status, and
rate of hypoxemia, as well as abnormal distribution of PESI
risk score. PESI risk class strongly predicted mortality, as did
admission to a hospital in the city of Philadelphia (OR, 1.30;
95% CI, 1.07-1.59) and admission to a teaching hospital
(OR, 1.27; 95% CI, 1.06-1.51). 
Conclusions: Patients with PE admitted on the weekend have
significantly higher short-term mortality than those admit-
ted on weekdays. Quality improvement efforts should be
aimed at providing a consistent approach to the manage-
ment of PE throughout the week.
Perspective: The data from this study and others seem com-
pelling that there is a detrimental effect on quality of care and
outcome of hospital admission at ‘off hours’ that is above and
beyond that associated with disease severity or comorbidity.
Health care services research should focus on identifying ele-
ments essential to quality care for acute illnesses, and then
also on the necessary scheduling and logistics to facilitate
Cardiovascular Surgery
Comparison of Early Surgery Versus Conventional
Treatment in Asymptomatic Severe Mitral
Regurgitation
Kang DH, Kim JH, Rim JH, et al.
Circulation 2009;119:797-804.
Study Question: Are there differences in long-term results
between early surgery and a more conventional treatment
strategy for surgical intervention among asymptomatic
patients with severe mitral regurgitation?
Methods: In an observational study of echocardiography /
Doppler examinations performed between 1996 and 2005, 447
consecutive asymptomatic patients (253 men, mean age 50 ±
15 years) with severe degenerative mitral regurgitation and
preserved left ventricular function were prospectively followed.
Early surgery was performed in 161 patients (151 mitral valve
repair, 10 mitral valve replacement), and the conventional
treatment strategy was followed in 286 patients.
Results: During a median follow-up of 1,988 days, there were
two repeat surgeries, but no operative or cardiac deaths in the
operated group, compared with 12 cardiac deaths, 1 repeat
surgery, and 22 admissions for congestive heart failure in the
conventional treatment group. The estimated actuarial 7-year
cardiac mortality rate was 0% in the operated group and 5 ±
2% in the conventional treatment group (p = 0.008). For 127
pairs matched by propensity score, the estimated actuarial 7-
year event-free survival was significantly higher in the
operated than in the conventional treatment group (99 ± 1%
vs. 85 ± 4%, p = 0.007). 
Conclusions: In asymptomatic patients with severe degenerative
mitral regurgitation, a strategy of early surgery was associated
with improved long-term outcomes compared with conserva-
tive management, mediated by lower cardiac mortality and
fewer hospitalizations for congestive heart failure.
Perspective: The 2006 American College of Cardiology /
American Heart Association guidelines include “prophylactic”
mitral valve repair as a Class IIa indication for surgical inter-
vention in asymptomatic patients with severe mitral
regurgitation. The recommendation is supported by data pub-
lished by the Mayo Clinic (N Engl J Med 1996;335:1417-23)
that suggest excess mortality in unoperated patients with
severe mitral regurgitation and no ‘conventional’ indication for
intervention. In contrast, literature from Vienna, Austria
(Circulation 2006;113:2238-44) suggests no excess mortality
associated with an approach of ‘watchful waiting.’ The present
study adds data supporting the former argument. The practi-
tioner still needs to critically consider potential risks and
benefits associated with surgical intervention, the skill of the
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delivery of health care at all hours; next we must move toward
providing these standards 24 hours a day.  
Summary written by: James B. Froehlich, MD
Heart Failure/Transplant
BNP-Guided vs Symptom-Guided Heart Failure
Therapy: The Trial of Intensified vs Standard
Medical Therapy in Elderly Patients with Congestive
Heart Failure (TIME-CHF) Randomized Trial 
Pfisterer M, Buser P, Rickli H, et al., on behalf of the TIME-CHF
Investigators.
JAMA 2009;301:383-392. 
Study Question: Is intensified heart failure (HF) therapy
guided by N-terminal brain natriuretic peptide (BNP) supe-
rior to symptom-guided therapy? 
Methods: This was a randomized controlled multicenter trial of
499 patients ages ≥60 years with systolic HF (left ventricular
ejection fraction [LVEF] <45%), New York Heart
Association (NYHA) class ≥II, prior hospitalization for HF
within 1 year, and N-terminal BNP level of ≥2 ULN. HF
patients underwent uptitration of guideline-based treatments
to reduce symptoms to NYHA class of ≥II (symptom-guided
therapy) and BNP level of ≤2 times ULN and symptoms to
NYHA class of ≤II (BNP-guided therapy).
Results: HF therapy guided by N-terminal BNP and symp-
tom-guided therapy resulted in similar rates of survival free of
all-cause hospitalizations (41% vs. 40%, respectively; p =
0.39). Over the 18-month follow-up, QOL metrics improved
and were similar in both strategies. Survival free of hospital-
ization for HF was higher among those in the N-terminal
BNP–guided group (72% vs. 62%, respectively; p = 0.01). HF
treatment guided by N-terminal BNP improved outcomes in
patients ages 60-75 years, but not in those ages ≥75 years (p <
0.02 for interaction).
Conclusions: In elderly patients, HF treatment guided by N-
terminal BNP did not improve overall clinical outcomes or
QOL when compared with symptom-guided treatment.
Perspective: The main advantages of evaluating BNP in HF are
for risk stratification, predicting mortality, confirming the
diagnosis, and monitoring therapy. Unlike the STARS-BNP
trial (J Am Coll Cardiol 2007;49:1733-9) and the
STARBRITE study (Am Heart J 2005;150:893-8), the find-
ings of this study suggest the superiority of symptoms to BNP
in monitoring response to therapy.  
Summary written by: Ragavendra R. Baliga, MBBS 
Interventional Cardiology
Percutaneous Coronary Intervention Versus
Coronary-Artery Bypass Grafting for Severe
Coronary Artery Disease
Serruys PW, Morice MC, Kappatein AP, et al., on behalf of the SYNTAX
Investigators.
N Engl J Med 2009;360:961-972. 
Study Question: What is the optimal revascularization strategy
for patients with severe coronary artery disease (CAD)?
Methods: The authors randomized 1,800 patients with three-
vessel CAD or left main CAD to coronary artery bypass
grafting (CABG) versus percutaneous coronary intervention
(PCI). All patients undergoing PCI were treated with pacli-
taxel-eluting stents. Patients who were eligible for only one
revascularization strategy (CABG or PCI) based on the spe-
cific anatomy were followed in a registry.
Results: The rate of major adverse cardiac events (MACE) at
1 year was significantly higher in the PCI arm (17.8% vs.
12.4% , p = 0.002), predominantly driven by a higher rate of
revascularization (13.5% vs. 5.9%). The outcome between
PCI and CABG was similar in patients with a low (≤22)
(13.6% vs. 14.7%), and intermediate SYNTAX score (16.7%
vs. 12%), whereas among patients with a high SYNTAX
score (>32), the MACE rate was significantly worse with
PCI (23.4% vs. 10.9%).
Conclusions: Among patients with three-vessel CAD or left
main CAD, CABG is associated with a lower risk of
MACE at 1 year compared with PCI.
Perspective: All the studies comparing PCI with CABG have
generally demonstrated similar survival, but an increased risk
of revascularization with PCI. The results of the SYNTAX
trial suggest that CABG should still be the preferred strategy,
especially in patients with a high SYNTAX score. On the
contrary, among patients with a low SYNTAX score, the
results of PCI were similar to that of CABG; thus, revascu-
larization should be guided by patient preference.  
Summary written by: Hitinder S. Gurm, MBBS
Cardiac Remote Ischemic Preconditioning in
Coronary Stenting (CRISP Stent) Study. A
Prospective, Randomized Control Trial
Hoole SP, Heck PM, Sharples L, et al.
Circulation 2009;119:820-827.
Study Question: Can remote ischemic preconditioning (IPC)
Results: No angiography was performed in 10,089 (43.1%)
patients, and of these, 4,818 (47.8%) were from hospitals
without catheterization laboratories. Patients with delay to
angiography were older, had more comorbidities, and had a
higher GRACE score. Mean time to angiography was 46
hours. Patients undergoing delayed angiography were more
likely to have recurrent in-hospital ischemia (33% vs. 22%),
reinfarction (8.4% vs. 5.0%), and heart failure (14% vs. 9.1%).
Major adverse cardiac event (MACE) rates from admission to
6 months increased with progressive delays to angiography.
Patients undergoing delayed angiography had better outcomes
than no angiography (MACE 18.9% vs. 22.2%, p = 0.015). 
Conclusions: A large proportion of patients with NSTE-ACS
do not undergo angiography. Higher risk, sicker patients
were more likely to have delays in angiography and were
more likely to have a higher rate of adverse events.
Perspective: This study demonstrates the marked variability in
treatment of ACS globally. It is, however, unclear if the worse
outcome in patients with prolonged time to angiography is a
reflection of underlying higher risk or is directly related to the
delay itself. Dedicated efforts are needed to rectify this imbal-
ance and improve the suboptimal care being provided to a
large proportion of patients with NSTE-ACS.  
Summary written by: Hitinder S. Gurm, MBBS 
Noninvasive Cardiology
Ionizing Radiation in Cardiac Imaging. A Science
Advisory From the American Heart Association
Committee on Cardiac Imaging of the Council on
Clinical Cardiology and Committee on
Cardiovascular Imaging and Intervention of the
Council on Cardiovascular Radiology and
Intervention
Gerber TC, Carr JJ, Arai AE, et al.
Circulation 2009;119:1056-1065.
Perspective: The collective dose received from medical uses of
radiation has increased >700% between 1980 and 2006. No
federal authority regulates radiation dose associated with
diagnostic imaging and intervention (with the exception of
mammography). This science advisory statement describes
the principles and uncertainties in estimating patient dose
and biological risk associated with ionizing radiation in car-
diac imaging, compares risks associated with medical
radiation exposure with background risks, and discusses risks
associated with failing to diagnose and treat in the absence
of imaging studies. The following are points to remember
about this advisory:  
be used to prevent myonecrosis in patients undergoing per-
cutaneous coronary intervention (PCI)?
Methods: The authors randomized 242 patients undergoing
elective PCI to receive remote IPC or control before arrival
to the cath lab. Remote IPC was induced by three 5-minute
inflations of a blood pressure cuff to 200 mm Hg around
the upper arm, followed by 5-minute intervals of reperfu-
sion. 
Results: There were no major procedural complications. The
median cardiac troponin I (cTNI) at 24 hours after PCI was
significantly lower in the remote IPC compared with the con-
trol group (0.06 vs. 0.16 ng/ml; p = 0.040). A larger number
of patients who received remote IPC had no detectable cTnI
release (48% vs. 29%; p < 0.005). At 6 months, patients ran-
domized to remote IPC had lower risk of the major adverse
cardiac and cerebral events (4 vs. 13 events; p = 0.018).
Conclusions: Remote IPC reduces myonecrosis in patients
undergoing PCI, and appears to reduce the risk of 6-month
major adverse events.
Perspective: IPC has been highly effective at reducing infarct
size in animal models, but its translation into clinical practice
has been hard to achieve since inducing transient ischemia of
vital organs safely is hard to achieve. Remote IPC appears to
provide similar benefits in animal models and has been previ-
ously demonstrated to reduce myonecrosis in patients
undergoing cardiac surgery. The results of this study suggest a
similar benefit in patients undergoing PCI and invoke the
need for definitive larger trials.  
Summary written by: Hitinder S. Gurm, MBBS 
Delay to Angiography and Outcomes Following
Presentation With High-Risk, Non–ST-Elevation
Acute Coronary Syndromes: Results From the
Global Registry of Acute Coronary Events
Swanson N, Montalescot G, Eagle KA, et al., on behalf of the GRACE
Investigators.
Heart 2009;95:211-215.
Study Question: How does delay to angiography impact out-
come of patients with non–ST-elevation acute coronary
syndromes (NSTE-ACS)?
Methods: The authors examined the outcome of 23,396
NSTE-ACS patients who were enrolled in the GRACE reg-
istry between 1999 and 2006. The authors assessed the
correlation between time to angiography and subsequent in-
hospital or post-discharge adverse outcomes. Patients were
subclassified into five groups based on time from admission
to angiography: less than 24 hours, 24–72 hours, 72 hours–7
days, greater than 7 days, or no angiography. 
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1. In 2006, computed tomography (CT) accounted for ~50%
of the collective dose of radiation received in conjunction with
diagnostic imaging; CT has an annual growth rate of >10%
per year. In 2006, cardiac CT accounted for 1.5% of CT radi-
ation dose, and use of this imaging modality likely will
increase. Nuclear medicine studies in the US accounted for
~25% of the collective radiation dose in 2006; cardiac studies
accounted for 57% of studies and ~85% of the radiation dose. 
2. Unlike radiation exposure, which can be measured, the
radiation dose to internal organs cannot be measured
directly, and organ doses are estimated using generic model-
ing techniques. 
3. Methods to estimate E have changed several times, mak-
ing it difficult to compare data previously reported despite
the use of the same description (effective radiation dose [E])
measured in the same units [mSv]). 
4. The biological consequences of exposure to ionizing radia-
tion fall into two general categories. 
• Deterministic effects predictably occur at a certain
absorbed dose to a specific tissue. Examples include
skin erythema, epilation, and cataract formation. 
• Stochastic, or random effects, occur with the interaction
between radiation exposure and cellular molecules.
Malignancy, the complication of greatest concern with
medical radiation exposure, is a stochastic effect of ion-
izing radiation. 
5. There are two hypotheses regarding radiation exposure
and cancer risk. 
• The linear no-threshold hypothesis holds that there is
no threshold below which radiation exposure does not
pose a risk of malignancy. The risk of malignancy is
extrapolated linearly from the cancer risk associated
with higher levels of radiation exposure.
• The linear-quadratic hypothesis holds that the risk of
malignancy associated with low doses of radiation expo-
sure are so low that they are impossible to quantify, but
that risk increases quadratically with doses at higher
levels. 
• The more conservative linear no-threshold hypothesis is
advocated by the Biological Effects of Ionizing
Radiation (BEIR) VII report of the National Research
Council of the National Academies. 
• The writing group for the present scientific advisory
notes that the linear no-threshold hypothesis is not sci-
entifically supported, and cannot be confirmed
observationally. 
6. Relative risk should be considered in addition to absolute
risk of malignancy associated with exposure to ionizing radi-
ation. 
7. The scientific advisory makes recommendations, including: 
• Studies that expose patients to ionizing radiation
should be ordered only after careful consideration of
potential benefit to the patient and in keeping with
appropriateness criteria. The risks of failing to diagnose
by not performing diagnostic studies also should be
considered. 
• Routine surveillance using testing that includes expo-
sure to ionizing radiation is not appropriate in
asymptomatic individuals at low risk. 
• For tests that are indicated, effort should be made to
reduce patient exposure to ionizing radiation. 
• The usefulness and societal value of lifetime tracking of
individual cumulative radiation dose are uncertain. 
• Imaging experts and manufacturers should continue to
work on developing consistent radiation output metrics,
and make this information an automatic part of the
imaging record. 
• The imaging community should participate in volun-
tary determination of diagnostic reference levels of
radiation dose to establish radiation dose benchmarks
for comparison.
Summary written by: David S. Bach, MD
Prevention/Vascular
Lipoprotein Particle Profiles by Nuclear Magnetic
Resonance Compared With Standard Lipid and
Apolipoproteins in Predicting Incident
Cardiovascular Disease in Women
Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM.
Circulation 2009;119:931-939.
Study Question: Are lipoprotein particle profiles a better pre-
dictor of cardiovascular (CV) risk among women?
Methods: Baseline lipoproteins were measured by nuclear mag-
netic resonance (NMR) spectroscopy in 27,673 apparently
healthy participants of the Women’s Health Study (WHS).
Women, ages 45 years or older at study entry (1992-1995),
were followed for a mean of 11 years, and 1,015 experienced a
CV event. CV endpoints were nonfatal myocardial infarction,
coronary revascularization, nonfatal ischemic stroke, and/or
CV death.
Results: Risk of CV disease (CVD) among those in the top
quintile of NMR-measured lipoprotein particle concentra-
tion (particles per liter) was hazard ratio (HR) 2.51 (95%
JACC Vol. 53, No. 14, 2009
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confidence interval [CI], 1.91-3.30) for low-density
lipoprotein (LDL), and for very LDL, the HR was 1.71
(95% CI, 1.38-2.12) compared to women in the bottom
quintile. For high-density lipoprotein (HDL), women in
the top quintile had a HR of 0.91 (95% CI, 0.75-1.12) for
CVD compared to the bottom quartile. The risk associated
with a ratio of low-density NMR to high-density NMR
was 2.25 (95% CI, 1.80-2.81). In the multivariate models
that examined NMR-measured lipoprotein particle size,
risks were 0.64 (95% CI, 0.52-0.79) for LDL NMR size,
0.65 (95% CI, 0.51-0.81) for HDL NMR size, and 1.37
(95% CI, 1.10-1.70) for very LDL NMR size. These HRs
were comparable to those using standard lipid measures, but
not superior (for LDL cholesterol 1.74 [95% CI, 1.40-
2.16], HDL cholesterol 0.52 [95% CI, 0.42-0.64],
non-HDL cholesterol 2.52 [95% CI, 1.95-3.25], and for
total/HDL cholesterol ratio 2.82 [95% CI, 2.23-3.58]).
Similar results were obtained when apolipoprotein measures
were used.
Conclusions: Use of NMR lipoprotein profiles was similar, but
not superior to standard lipid measures in CVD risk predic-
tion for apparently healthy women.
Perspective: These findings suggest that routine use of NMR
for risk assessment, particularly among apparently healthy
women, may not be cost-effective since a standard lipid pro-
file appears to be comparable. However, for populations that
were not examined in this study, including men, minority
populations, and those at high risk for CVD or with a his-
tory of CVD, further studies are warranted.  
Summary written by: Elizabeth A. Jackson, MD 
Mediterranean Diet and Incidence of and Mortality
From Coronary Heart Disease and Stroke in Women
Fung TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC, Hu FB.
Circulation 2009;119:1093-1100.
Study Question: Does adherence to a Mediterranean-type diet
reduce risk for cardiovascular disease (CVD) among
women?
Methods: Participants from the Nurses’ Health Study (NHS)
cohort, who were apparently healthy at baseline and fol-
lowed for the occurrence of coronary heart disease (CHD)
and stroke events, comprised the study population. An alter-
native Mediterranean Diet Score based on self-reported
dietary information was created. Points were counted if
women reported consumption higher than the median for
vegetables, fruits, nuts, whole grains, legumes, fish, and
alcohol. The ratio of monounsaturated to saturated fats, and
red and processed meat consumption below the median was
also included in the diet score. Dietary information was col-
lected through a food frequency questionnaire at six differ-
ent time points from 1984 to 2002.
Results: A total of 74,886 women, ages 38-63, were included
in this analysis. Over the 20 years of follow-up, 2,391 inci-
dent cases of CHD, 1,763 incident cases of stroke, and
1,077 incident cases of CVD deaths occurred. Women in
the top quintile for the Mediterranean Diet Score were at
lower risk for CHD events (relative risk [RR], 0.71; 95%
confidence interval [CI], 0.62-0.82) and stroke (RR, 0.87;
95% CI, 0.73-1.02) compared to those in the bottom quin-
tile. CVD mortality was also significantly lower among
women in the top quintile (RR, 0.61; 95% CI, 0.49-0.76). 
Conclusions: Adherence to a Mediterranean-type diet is asso-
ciated with a protective benefit for CHD and stroke among
women.
Perspective: These findings add to current evidence that
adoption and adherence to a diet high in plant proteins and
fish, and lower consumption of animal products and satu-
rated fats, is associated with lower risk for CVD. Still, this
type of diet is often difficult for Americans to adhere to for
multiple reasons, including cost.  
Summary written by: Elizabeth A. Jackson, MD
Long-Term Antihypertensive Efficacy and Safety of
the Oral Direct Renin Inhibitor Aliskiren: A 12-
Month Randomized, Double-Blind Comparator
Trial With Hydrochlorothiazide
Schmieder RE, Philipp T, Guerediaga J, et al.
Circulation 2009;119:417-425.
Study Question: What is the long-term efficacy and safety of
an antihypertensive regimen based on aliskiren versus an
antihypertensive regimen based on hydrochlorothiazide?
Methods: This was a randomized double-blind parallel-group
active-control dose titration study of an antihypertensive
regimen based on aliskiren 150 mg versus hydrochloro–
thiazide 12.5 mg or a placebo daily. There was a 2- to 4-
week placebo run-in, and forced titration to aliskiren 300
mg or hydrochlorothiazide 25 mg at week 3 and addition of
amlodipine 5 mg at week 12 and titrated to 10 mg at week
18 for patients whose blood pressure remained uncontrolled.
Entry criterion was a sitting diastolic blood pressure
between 95 and 109 mm Hg.
Results: Blood pressure reduction was significantly greater
with aliskiren versus hydrochlorothiazide at week 26 
(-20.3/-14.2 vs. -18.6/-13.0 mm Hg, respectively; p < 0.05)
and persisted through week 52. Aliskiren was superior to
hydrochlorothiazide in reducing blood pressure during the
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monotherapy period as well (-17.4/-12.2 vs. -14.7/-
10.3 mm Hg; p < 0.001). Reported adverse events were sim-
ilar in the two groups (65.2% vs. 61.5%). There was more
hypokalemia in the hydrochlorothiazide group versus the
aliskiren group (17.9% vs. 0.9%, respectively; p < 0.0001). 
Conclusions: Aliskiren provided significantly greater blood
pressure reduction than hydrochlorothiazide, both as
monotherapy and with the optional addition of amlodipine.
Aliskiren therapy was well tolerated, and direct renin inhibi-
tion with aliskiren represents an effective option for the
long-term treatment of essential hypertension.
Perspective: This study suggests that a new class of antihyper-
tensive agents has been added to our armamentarium, in the
form of renin inhibition. The role of renin inhibition in the
treatment of hypertension remains unclear, however, as it
still remains well behind many other antihypertensive treat-
ments in terms of long-term follow-up efficacy, safety, and
proven benefit in reducing cardiovascular endpoints. Given
this, most clinicians need proof of either a significant superi-
ority in preventing these endpoints, or a compelling drug
class benefit, to identify the role of renin inhibition in the
treatment of hypertension.  
Summary written by: James B. Froehlich, MD
Omega-6 Fatty Acids and Risk for Cardiovascular
Disease. A Science Advisory From the American Heart
Association Nutrition Subcommittee of the Council on
Nutrition, Physical Activity, and Metabolism; Council
on Epidemiology and Prevention
Harris WS, Mozaffarian D, Rimm E, et al. 
Circulation 2009;119:902-907.
Perspective: The following are 10 points to remember about
omega-6 fatty acids and risk for cardiovascular disease:
1. While there is agreement that atherosclerosis is increased in
persons who consume a diet high in saturated fat, there is
debate as to whether dietary omega-6 (or n-6) polyunsatu-
rated fatty acids (PUFAs) increase or reduce risk for coronary
heart disease (CHD). 
2. Linoleic acid (LA), whose primary source is vegetable oils,
is the primary dietary omega-6 PUFA and is the precursor
to metabolically important omega-6 PUFA arachidonic acid
(AA). Those who feel that omega-6 PUFAs should be lim-
ited, argue that AA is the substrate for the synthesis of a
variety of pro-inflammatory cytokines and increases the sus-
ceptibility of low-density lipoprotein (LDL) to oxidation.
3. The argument for liberal use of omega-6 PUFAs is
founded on epidemiologic and clinical trial data, and that AA
is also a substrate for anti-inflammatory cytokines, prostacy-
clins, and other vasodilators. 
4. Increasing dietary LA in exchange for carbohydrates
decreases the ratio of cholesterol to high-density lipopro-
tein cholesterol (HDL-C) greater than is seen for other
fatty acids. The replacement of 10% of calories from 
saturated fatty acid with omega-6 PUFA is associated with
an 18 mg/dl decrease in LDL-C, which is greater than 
that observed with similar replacement with carbohydrate,
and beyond that produced by the removal of saturated 
fatty acids. 
5. Higher LA intakes may improve insulin resistance, reduce
the incidence of diabetes mellitus, and is associated with
lower blood pressure. 
6. Most prospective studies of nutrition and cardiovascular
event rate show no difference or a lower cerebrovascular
event, both coronary and stroke, in persons with a higher
intake and blood level of LA. A meta-analysis of six of the
trials indicated that replacing saturated fatty acids with
PUFAs lowered the risk for CHD events by 24%.
7. The combined results of these studies and the observa-
tional trials provide evidence that replacing saturated fatty
acid or refined carbohydrate (e.g., sugars, white bread, white
rice, potatoes) with omega-6 PUFAs reduces CHD risk. 
8. The 2005 Dietary Guidelines for Americans support an
acceptable macronutrient distribution range of 5-10% dietary
energy from omega-6 PUFAs. 
9. Advice to reduce omega-6 PUFA intakes is typically
framed as a call to lower the ratio of dietary omega-6 to
omega-3 PUFAs. Although increasing omega-3 PUFA tis-
sue levels does reduce the risk for CHD, it does not follow
that decreasing omega-6 levels will do the same. 
10. The American Heart Association (AHA) supports an
omega-6 PUFA intake of at least 5-10% of energy in the
context of other AHA lifestyle and dietary recommendations.
To reduce omega-6 PUFA intakes from their current levels
would be more likely to increase than to decrease risk for
CHD. The data also suggest that higher intakes appear to be
safe and may be even more beneficial (as part of a low–satu-
rated-fat, low-cholesterol diet).  
Summary written by: Melvyn Rubenfire, MD 
These journal article summaries were extracted from
Cardiosource, your source for the best in cardiovascular
information and education. www.cardiosource.com
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